These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29666227)

  • 21. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
    Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
    Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.
    Abbott RK; Lee JH; Menis S; Skog P; Rossi M; Ota T; Kulp DW; Bhullar D; Kalyuzhniy O; Havenar-Daughton C; Schief WR; Nemazee D; Crotty S
    Immunity; 2018 Jan; 48(1):133-146.e6. PubMed ID: 29287996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
    Zhang R; Verkoczy L; Wiehe K; Munir Alam S; Nicely NI; Santra S; Bradley T; Pemble CW; Zhang J; Gao F; Montefiori DC; Bouton-Verville H; Kelsoe G; Larimore K; Greenberg PD; Parks R; Foulger A; Peel JN; Luo K; Lu X; Trama AM; Vandergrift N; Tomaras GD; Kepler TB; Moody MA; Liao HX; Haynes BF
    Sci Transl Med; 2016 Apr; 8(336):336ra62. PubMed ID: 27122615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
    Moore PL; Gorman J; Doria-Rose NA; Morris L
    Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.
    Bancroft T; DeBuysscher BL; Weidle C; Schwartz A; Wall A; Gray MD; Feng J; Steach HR; Fitzpatrick KS; Gewe MM; Skog PD; Doyle-Cooper C; Ota T; Strong RK; Nemazee D; Pancera M; Stamatatos L; McGuire AT; Taylor JJ
    J Exp Med; 2019 Oct; 216(10):2331-2347. PubMed ID: 31345930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.
    Verkoczy L
    Adv Immunol; 2017; 134():235-352. PubMed ID: 28413022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailored immunogens for rationally designed antibody-based HIV-1 vaccines.
    Mouquet H
    Trends Immunol; 2015 Aug; 36(8):437-9. PubMed ID: 26169255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Model for Potential B-cell Precursors of Broadly Neutralizing HIV-1 Antibodies Selection and Antibody Affinity Maturation.
    Metlas R; Srdic-Rajic T
    AIDS Rev; 2019; 21(1):23-27. PubMed ID: 30899117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
    Patricia D'Souza M; Allen MA; Baumblatt JAG; Boggiano C; Crotty S; Grady C; Havenar-Daughton C; Heit A; Hu DJ; Kunwar N; McElrath MJ;
    Vaccine; 2018 Sep; 36(38):5671-5677. PubMed ID: 30097219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.
    Alam SM; Aussedat B; Vohra Y; Meyerhoff RR; Cale EM; Walkowicz WE; Radakovich NA; Anasti K; Armand L; Parks R; Sutherland L; Scearce R; Joyce MG; Pancera M; Druz A; Georgiev IS; Von Holle T; Eaton A; Fox C; Reed SG; Louder M; Bailer RT; Morris L; Abdool-Karim SS; Cohen M; Liao HX; Montefiori DC; Park PK; Fernández-Tejada A; Wiehe K; Santra S; Kepler TB; Saunders KO; Sodroski J; Kwong PD; Mascola JR; Bonsignori M; Moody MA; Danishefsky S; Haynes BF
    Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
    Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
    Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.
    Kepler TB; Wiehe K
    Immunol Rev; 2017 Jan; 275(1):129-144. PubMed ID: 28133793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.